XENE at a glance
Xenon Pharmaceuticals Inc. (XENE, SEC CIK 1582313) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on August 6, 2026 and Form 4 insider filings as recently as October 1, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Xenon Pharmaceuticals Inc. (XENE) reported revenue of $7.5 million and a net loss of $345.9 million. Diluted EPS was -$4.36.
- As of June 30, 2026, 32 institutional investment managers tracked by SignalX reported holding Xenon Pharmaceuticals Inc. (XENE) shares worth $2.1 billion in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by Kelly Thomas Patrick on September 30, 2026 of 15,000 shares at $37.32 per share.
- In the last 90 days, XENE insiders reported 2 open-market purchases ($1.7M) and 3 open-market sales ($1.1M) on Form 4, a net purchase of $615K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $7.5M
- 10-K XBRL
- Insiders · 90 days
- 2 buys · 3 sells
- Net +$615K
- 13F holders
- 32 funds
- $2.1B · +3 vs prior quarter
- Latest 8-K
- Aug 6, 2026
- Item 2.02 · Item 7.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business model: neuroscience-focused biopharma discovering and commercializing novel ion channel modulators for neurological and psychiatric disorders
- New emphasis on azetukalner in Phase 3 for epilepsy (FOS and PGTCS) and depression (MDD and BPD), with multiple late-stage studies ongoing
- Strategic shift: advancing first Kv7 potassium channel opener with potential rapid onset and once-daily dosing, targeting difficult-to-treat epilepsy and neuropsychiatric indications
- Notable metric: 380 patients enrolled in pivotal Phase 3 FOS study (X-TOLE2), seizure reduction up to 52.8% at 25 mg dose, ongoing 7-year open label extension with 46% retention at 48 months
- Early-stage pipeline expansion into pain with initiation of Phase 1 studies for two novel candidates targeting Nav1.7 and Kv7 channels, exploiting genetic validation for new pain treatments
Risk Factors
- Regulatory risk: alignment with Japan’s PMDA to enroll ~60 of 360 X-TOLE3 participants in Japan, affecting regulatory submission timing
- Macroeconomic risk: foreign exchange exposure to Canadian dollar fluctuations impacting monetary assets and liabilities
- Operational risk: reliance on successful completion of late-stage Phase 3 clinical trials for azetukalner, including X-TOLE2 topline data expected March 2026
- Competitive risk: collaboration with Neurocrine Biosciences on NBI-921355, targeting epilepsy, poses potential competitive or partnership dependency risks
- Financial risk: accumulated deficit $1.245 billion, net losses increasing to $345.9 million in 2025, requiring ongoing equity/debt financing with no product sales revenue yet
Management Discussion & Analysis
- Cash flow, buybacks, dividends, or capital expenditure figures not included
- Forward-looking statements involve risks and uncertainties, no specific guidance or outlook provided
AI summary of the XENE 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Risk Factors
- No newly triggered risk identified; filing does not compare changes with the prior 10-K
- Phase 3 execution risk for azetukalner, with no prior experience completing Phase 3 studies or filing an NDA
- Regulatory compliance exposure from misconduct, including inaccurate clinical data, healthcare fraud, kickbacks, and privacy violations
- Competitive risk from safer, more effective, convenient, or lower-priced anti-seizure and antidepressant therapies
- Funding risk despite cash runway of at least 12 months, with net losses of $213.0 million for the six months ended June 30, 2026
AI summary of the XENE 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q2 and first-half 2026 financial results announced for periods ended June 30, 2026
- Exhibit 99.1 contains the substantive results and management commentary
Item 7.01: Regulation FD Disclosure
- Investor communications may contain material information across SEC filings, press releases, calls, company websites, and social media
- Key monitoring channels include @XenonPharma on X, LinkedIn, and investor news releases
Item EX-99.1: Item EX-99.1
- Q2 2026 net loss $110.7M versus $84.7M, reflecting accelerated investment in azetukalner and pain programs
- Cash, equivalents and marketable securities $1.245B, supporting operations into 2029 and reducing near-term financing risk
Item 5.07: Submission of Matters to a Vote of Security Holders
- 93.54% shareholder participation, with 90,399,636.29 shares voted or represented by proxy
- All eight director nominees elected through 2027, with opposition ranging from 388,586.65 to 4,517,221.65 votes
Item 2.02: Results of Operations and Financial Condition
- Q1 2026 financial results announced for the three months ended March 31, 2026
- Detailed results and management commentary available in Exhibit 99.1
Item 7.01: Regulation FD Disclosure
- Expanded investor-information channels, including SEC filings, press releases, conferences, websites, and social media
- Social-media disclosures may contain material information relevant to investors
AI summaries of XENE 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for XENE
Don't miss the next XENE filing
- Alerts as it files. A push when XENE files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut XENE, by share count.
- Ask anything. An AI agent that reads every XENE filing and answers with sources.
XENE alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Kelly Thomas Patrick | Buy | Sep 30, 2026 | 15,000 | $37.32 |
| MORTIMER IAN | Buy | Sep 30, 2026 | 30,000 | $37.38 |
| Svoronos Dawn | M | Sep 1, 2026 | 5,144 | - |
| Svoronos Dawn | M | Sep 1, 2026 | 5,144 | $8.15 |
| KENNEY CHRISTOPHER JOHN | Sell | Aug 28, 2026 | 700 | $60.98 |
| KENNEY CHRISTOPHER JOHN | Sell | Aug 28, 2026 | 6,368 | $60.17 |
| GANNON STEVEN | Sell | Aug 11, 2026 | 10,000 | $64.06 |
| PATOU GARY | Sell | Jun 5, 2026 | 1,322 | $53.14 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $0 | $7.5M |
| Operating Income | - | -$279.3M | -$373.1M |
| Net Income | -$182.4M | -$234.3M | -$345.9M |
| Op. Margin | - | - | -4974.3% |
| Net Margin | - | - | -4612.1% |
| Balance Sheet | |||
| Total Assets | - | $798.1M | $633.2M |
| Equity | $927.9M | $754.9M | $581.8M |
| ROE | -19.7% | -31.0% | -59.5% |
| Per Share | |||
| EPS | $-2.73 | $-3.01 | $-4.36 |
| Cash Flow | |||
| Operating CF | - | -$181.4M | -$279.1M |
| CapEx | $5.6M | $3.1M | $799K |
Source: XBRL data in Xenon Pharmaceuticals Inc. (XENE)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate XENE share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 32 | $2.14B |
| Q1 2026 | 29 | $1.74B |
| Q4 2025 | 26 | $1.08B |
| Q3 2025 | 27 | $1.01B |
| Q2 2025 | 25 | $711.7M |
| Q1 2025 | 23 | $469.6M |
| Q4 2024 | 19 | $415.3M |
| Q3 2024 | 16 | $121.2M |
- T. Rowe Price Group+1.92M (+144%)
- BlackRock+1.88M (+33%)
- Two Sigma Investments+1.04M (+171%)
- Invesco Ltd+844.4K (+1429%)
- JPMorgan Chase & Co+693.8K (+36%)
- Citadel Advisors LLC−1.25M (-47%)
- FMR LLC (Fidelity)−1.17M (-11%)
- Renaissance Technologies LLC−113.4K (-38%)
- Morgan Stanley−67.5K (-14%)
- Raymond James Financial−2.1K (-2%)
- Dimensional Fund Advisors+36.6K
- Allstate+8.2K
- Blackstone Group+7.6K
Source: 13F-HR filings on SEC EDGAR (aggregated from 197 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
XENE filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Oct 1, 2026 | - | - | - |
| 4 | Oct 1, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Aug 31, 2026 | - | - | - |
| 4 | Aug 13, 2026 | - | - | - |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 8-K | Jun 3, 2026 | - | Analysis | |
| 4 | May 13, 2026 | - | - | |
| 8-K | May 7, 2026 | - | Analysis | |
| 10-Q | May 7, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | Apr 13, 2026 | - | Analysis | - |
| 4 | Mar 13, 2026 | - | - | - |
| 4 | Mar 13, 2026 | - | - | - |
| 8-K | Mar 13, 2026 | - | Analysis | - |
| 4 | Mar 13, 2026 | - | - | - |
| 8-K | Mar 12, 2026 | - | Analysis | - |
| 4 | Mar 11, 2026 | - | - | - |
| 4 | Mar 11, 2026 | - | - | - |
| 4 | Mar 11, 2026 | - | - | - |
| 8-K | Mar 9, 2026 | - | Analysis | - |
| 8-K | Feb 27, 2026 | - | Analysis | - |
| 10-K | Feb 26, 2026 | Dec 31, 2025 | Analysis |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
XENE SEC filings: frequently asked questions
Are XENE insiders buying or selling?
In the last 90 days, Xenon Pharmaceuticals Inc. (XENE) officers, directors and 10% owners reported 2 open-market purchases worth $1.7 million by 2 insiders and 3 open-market sales worth $1.1 million by 2 insiders on Form 4, a net purchase of $614,761. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold XENE stock?
As of June 30, 2026, the largest Xenon Pharmaceuticals Inc. (XENE) holders among the 13F filers tracked by SignalX were FMR LLC (Fidelity) ($582.4 million), BlackRock ($454.1 million), T. Rowe Price Group ($196.1 million), JPMorgan Chase & Co ($157.4 million), State Street Corp ($118.9 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was XENE's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Xenon Pharmaceuticals Inc. (XENE) reported revenue of $7.5 million and a net loss of $345.9 million. Diluted EPS was -$4.36. The figures come from the XBRL data in the 10-K.
What are the main risks in XENE's latest 10-K?
In the 10-K filed February 26, 2026, Xenon Pharmaceuticals Inc. (XENE) flagged: Regulatory risk: alignment with Japan’s PMDA to enroll ~60 of 360 X-TOLE3 participants in Japan, affecting regulatory submission timing. Macroeconomic risk: foreign exchange exposure to Canadian dollar fluctuations impacting monetary assets and liabilities. (AI summary of the Risk Factors section.)
What did XENE report in its latest 8-K?
Xenon Pharmaceuticals Inc. (XENE) filed an 8-K on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure). Q2 and first-half 2026 financial results announced for periods ended June 30, 2026.
What are the latest XENE SEC filings?
Xenon Pharmaceuticals Inc. (XENE) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on August 6, 2026 and a Form 4 insider filing on October 1, 2026.
What is XENE's SEC CIK number?
Xenon Pharmaceuticals Inc. (XENE)'s SEC Central Index Key (CIK) is 1582313. EDGAR lists every XENE filing under that number.
Ask anything about XENE
The research agent reads XENE's filings, financials, insider trades and 13F holders, then answers with sources.